• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Filling the gap between Guidelines and Real World in the cardiovascular approach to the diabetic patients: the need for a call to action.

作者信息

Maranta Francesco, Cianfanelli Lorenzo, Rizzo Manfredi, Cianflone Domenico

机构信息

Cardiac Rehabilitation Unit, San Raffaele Scientific Institute, Milan, Italy.

Cardiac Rehabilitation Unit, San Raffaele Scientific Institute, Milan, Italy.

出版信息

Int J Cardiol. 2021 Apr 15;329:205-207. doi: 10.1016/j.ijcard.2020.12.074. Epub 2020 Dec 31.

DOI:10.1016/j.ijcard.2020.12.074
PMID:33388398
Abstract
摘要

相似文献

1
Filling the gap between Guidelines and Real World in the cardiovascular approach to the diabetic patients: the need for a call to action.填补糖尿病患者心血管疾病治疗指南与现实世界之间的差距：需要采取行动呼吁。
Int J Cardiol. 2021 Apr 15;329:205-207. doi: 10.1016/j.ijcard.2020.12.074. Epub 2020 Dec 31.
2
Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.新型降糖药物与二甲双胍联合治疗 2 型糖尿病的心血管疗效的性别差异。
J Am Heart Assoc. 2020 Jan 7;9(1):e012940. doi: 10.1161/JAHA.119.012940. Epub 2020 Jan 4.
3
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.钠-葡萄糖共转运蛋白 2 抑制剂与其他降糖药物治疗 2 型糖尿病患者的心血管死亡率和发病率（CVD-REAL Nordic）：一项多国观察性分析。
Lancet Diabetes Endocrinol. 2017 Sep;5(9):709-717. doi: 10.1016/S2213-8587(17)30258-9. Epub 2017 Aug 3.
4
Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.2 型糖尿病合并心血管疾病患者的降糖治疗。
Eur J Prev Cardiol. 2019 Dec;26(2_suppl):73-80. doi: 10.1177/2047487319880040.
5
SGLT2 inhibitors for primary prevention of cardiovascular events.用于心血管事件一级预防的钠-葡萄糖协同转运蛋白2抑制剂
J Diabetes. 2020 Jan;12(1):5-7. doi: 10.1111/1753-0407.13004. Epub 2019 Nov 21.
6
Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes.降糖药物与心力衰竭： 2 型糖尿病心血管结局试验的启示。
Diabetes Res Clin Pract. 2019 Nov;157:107835. doi: 10.1016/j.diabres.2019.107835. Epub 2019 Aug 31.
7
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.SGLT-2 抑制剂与其他降血糖药物相关的心血管事件：CVD-REAL 2 研究。
J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639. doi: 10.1016/j.jacc.2018.03.009. Epub 2018 Mar 11.
8
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.SGLT2（钠-葡萄糖共转运蛋白 2）抑制剂和 GLP-1（胰高血糖素样肽-1）受体激动剂如何降低心血管结局？：已完成和正在进行的机制试验。
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):506-522. doi: 10.1161/ATVBAHA.119.311904. Epub 2020 Jan 30.
9
Risk factor reduction in type 2 diabetes demands a multifactorial approach.2 型糖尿病的风险因素降低需要采取多因素方法。
Eur J Prev Cardiol. 2019 Dec;26(2_suppl):81-91. doi: 10.1177/2047487319872015.
10
Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis.新型降糖药物与2型糖尿病患者发生心血管及不良事件的风险较低相关：一项基于人群的分析。
Int J Cardiol. 2020 Jul 1;310:147-154. doi: 10.1016/j.ijcard.2020.03.025. Epub 2020 Apr 15.

引用本文的文献

1
Triglyceride/high density lipoprotein cholesterol index and future cardiovascular events in diabetic patients without known cardiovascular disease.甘油三酯/高密度脂蛋白胆固醇指数与无已知心血管疾病的糖尿病患者未来心血管事件的关系
Sci Rep. 2025 Mar 17;15(1):9217. doi: 10.1038/s41598-025-92933-6.
2
Effect of Antidiabetic Therapy on Clinical Outcomes of COVID-19 Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis.抗糖尿病治疗对 2 型糖尿病合并 COVID-19 患者临床结局的影响：系统评价和荟萃分析。
Ann Pharmacother. 2023 Jul;57(7):776-786. doi: 10.1177/10600280221133577. Epub 2022 Oct 29.
3
The Role of Physicians' Digital Tools in Pharmacological Management of Type 2 Diabetes Mellitus.
医生数字工具在 2 型糖尿病药物管理中的作用。
Medicina (Kaunas). 2022 Aug 6;58(8):1061. doi: 10.3390/medicina58081061.
4
Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS).口服司美格鲁肽对2型糖尿病患者心血管参数及其机制的影响：司美格鲁肽抗动脉粥样硬化作用机制研究（SAMAS）的原理与设计
Diabetes Ther. 2022 Apr;13(4):795-810. doi: 10.1007/s13300-022-01226-y. Epub 2022 Mar 8.
5
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.在葡萄牙，口服司美格鲁肽与恩格列净和度拉鲁肽的长期成本效益比较
Diabetol Metab Syndr. 2022 Feb 14;14(1):32. doi: 10.1186/s13098-022-00801-4.
6
Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options.脂蛋白与心血管疾病：致动脉粥样硬化的小而密低密度脂蛋白的临床意义及新治疗选择的最新进展
Biomedicines. 2021 Oct 29;9(11):1579. doi: 10.3390/biomedicines9111579.
7
Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review.新型抗糖尿病药物在2型糖尿病合并COVID-19患者中的应用：一项批判性综述。
Diabetes Ther. 2021 Dec;12(12):3037-3054. doi: 10.1007/s13300-021-01170-3. Epub 2021 Oct 26.
8
Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective.脂质代谢紊乱诊断与治疗中的挑战与机遇：新见解与未来展望
Metabolites. 2021 Sep 9;11(9):611. doi: 10.3390/metabo11090611.
9
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism.胰高血糖素样肽-1受体激动剂在新冠疫情期间的作用：一种假设的分子机制。
Expert Opin Drug Saf. 2021 Nov;20(11):1309-1315. doi: 10.1080/14740338.2021.1970744. Epub 2021 Aug 25.
10
Incretin-based therapies in 2021 - Current status and perspectives for the future.2021年基于肠促胰岛素的疗法——现状与未来展望
Metabolism. 2021 Sep;122:154843. doi: 10.1016/j.metabol.2021.154843. Epub 2021 Jul 30.